• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Ord Shs (OP: TKPHF )

    25.93 UNCHANGED
    Streaming Delayed Price Updated: 11:13 AM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Takeda Pharmaceutical Ord Shs

    < Previous 1 2 Next >
    Current Analysis: Takeda Pharmaceutical
    Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of... 
    Via Talk Markets
    Current Analysis: Takeda Pharmaceuticals (TKPHF)
    TKPHF is the largest Japanese drug company. Furthermore the estimated $45.50 dividend income from $1k invested is about 1.64 times greater than Friday’s price of a single share 
    Via Talk Markets
    Takeda Moves Out From Licensing Agreement With Theravance Biopharma
    In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'... 
    Via Benzinga
    Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
    Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its  
    Via Benzinga
    United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
    The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
    Via Benzinga
    Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
    Via Benzinga
    Takeda's Dengue Vaccine Candidate Under FDA Priority Review
    Via Benzinga
    Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
    Via Benzinga
    Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
    Via Benzinga
    Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
    Via Benzinga
    Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
    Via Benzinga
    Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
    Via Benzinga
    Why Shares of Phathom Pharmaceutical Jumped This Week
    Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy. 
    Via The Motley Fool
    Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
    Via Benzinga
    Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
    From Singapore Economic Development Board (EDB)A*STAR
    Via ACN Newswire
    Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
    Via Benzinga
    Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
    Via Benzinga
    Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
    Via Benzinga
    With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
    Via Benzinga
    After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
    Via Benzinga
    EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
    BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
    Via Benzinga
    Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
    Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
    Via Benzinga
    FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
    The  
    Via Benzinga
    Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
    Via Benzinga
    Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
    Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
    Via Benzinga
    Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
    Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
    Via Benzinga
    Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
    Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four... 
    Via Benzinga
    Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
    Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of... 
    Via Benzinga
    FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
    Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral... 
    Via Benzinga
    Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
    Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd... 
    Via Benzinga
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.